Pharvaris (PHVS) News Today $19.54 +0.42 (+2.20%) As of 01/22/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Leerink Partnrs Comments on Pharvaris FY2026 EarningsJanuary 23 at 2:45 AM | americanbankingnews.comPharvaris FY2026 EPS Estimate Reduced by Leerink PartnrsPharvaris (NASDAQ:PHVS - Free Report) - Investment analysts at Leerink Partnrs dropped their FY2026 earnings per share estimates for Pharvaris in a report released on Monday, January 20th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings of ($2.87) per share forJanuary 22 at 7:35 AM | marketbeat.comPharvaris (NASDAQ:PHVS) Shares Up 5.3% - Here's WhyPharvaris (NASDAQ:PHVS) Stock Price Up 5.3% - Here's WhyJanuary 21 at 1:31 PM | marketbeat.comBank of America Securities Sticks to Their Sell Rating for Pharvaris (PHVS)January 16, 2025 | markets.businessinsider.comPharvaris Positioned for Growth: Strategic Focus on Deucrictibant and Financial Stability Drive Buy RatingJanuary 15, 2025 | markets.businessinsider.comPharvaris (NASDAQ:PHVS) Shares Down 11.7% - Here's What HappenedPharvaris (NASDAQ:PHVS) Shares Down 11.7% - What's Next?January 13, 2025 | marketbeat.comPharvaris N.V.: Pharvaris Outlines 2025 Strategic PrioritiesJanuary 13, 2025 | finanznachrichten.dePharvaris Outlines 2025 Strategic PrioritiesJanuary 13, 2025 | globenewswire.comJane Street Group LLC Makes New Investment in Pharvaris (NASDAQ:PHVS)Jane Street Group LLC purchased a new position in Pharvaris (NASDAQ:PHVS - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 28,418 shares of the company's stock, valued at approximately $526,000. Jane StJanuary 6, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Sees Large Volume Increase - Here's What HappenedPharvaris (NASDAQ:PHVS) Sees Strong Trading Volume - Time to Buy?January 3, 2025 | marketbeat.comState Street Corp Purchases New Shares in Pharvaris (NASDAQ:PHVS)State Street Corp acquired a new position in Pharvaris (NASDAQ:PHVS - Free Report) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 53,980 shares of the company's stock, valued at approximateJanuary 3, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Trading Down 3.5% - Here's WhyPharvaris (NASDAQ:PHVS) Shares Down 3.5% - Time to Sell?December 31, 2024 | marketbeat.comPharvaris: Despite 30% Decline, Still Fair At BestDecember 29, 2024 | seekingalpha.comPharvaris (NASDAQ:PHVS) Sees Significant Drop in Short InterestPharvaris (NASDAQ:PHVS - Get Free Report) was the recipient of a large drop in short interest in December. As of December 15th, there was short interest totalling 152,100 shares, a drop of 24.8% from the November 30th total of 202,200 shares. Approximately 0.9% of the shares of the stock are short sold. Based on an average trading volume of 85,200 shares, the short-interest ratio is presently 1.8 days.December 28, 2024 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Invests $906,000 in Pharvaris (NASDAQ:PHVS)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in Pharvaris (NASDAQ:PHVS - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 48,896 shares of the company's stock,December 20, 2024 | marketbeat.comPharvaris price target lowered to $46 from $50 at JMP SecuritiesDecember 6, 2024 | markets.businessinsider.comPharvaris Reports Q3 2024 Progress and FinancialsNovember 25, 2024 | tipranks.comOppenheimer Remains a Buy on Pharvaris (PHVS)November 15, 2024 | markets.businessinsider.comPharvaris Advances in HAE Treatment with Strong FinancialsNovember 14, 2024 | markets.businessinsider.comPharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business UpdatesNovember 13, 2024 | globenewswire.comPharvaris to Participate in the Guggenheim Healthcare Innovation ConferenceNovember 12, 2024 | globenewswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Waters (WAT), Pharvaris (PHVS) and Tandem Diabetes Care (TNDM)November 12, 2024 | markets.businessinsider.comPharvaris (NASDAQ:PHVS) Stock Quotes, Forecast and News SummaryOctober 29, 2024 | benzinga.comPharvaris’s Promising Developments in HAE Treatment Drive Buy RatingOctober 26, 2024 | markets.businessinsider.comPharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific MeetingOctober 24, 2024 | markets.businessinsider.comPharvaris (PHVS) Receives a Buy from Morgan StanleyOctober 22, 2024 | markets.businessinsider.comPharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific MeetingsOctober 16, 2024 | globenewswire.comPharvaris to Host Virtual Investor Event on October 23, 2024October 15, 2024 | globenewswire.comOppenheimer Sticks to Their Buy Rating for Pharvaris (PHVS)October 15, 2024 | markets.businessinsider.comMorgan Stanley Reaffirms Their Buy Rating on Pharvaris (PHVS)October 15, 2024 | markets.businessinsider.comPharvaris (PHVS) Gets a Buy from Morgan StanleyOctober 7, 2024 | markets.businessinsider.comPharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership WorkshopOctober 3, 2024 | globenewswire.comNovo Holdings A S Has $32.43 Million Stock Position in Pharvaris (NASDAQ:PHVS)Novo Holdings A S raised its holdings in shares of Pharvaris (NASDAQ:PHVS - Free Report) by 47.7% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,725,000 shares of the company's stock after purchasing anSeptember 30, 2024 | marketbeat.comMorgan Stanley Keeps Their Buy Rating on Pharvaris (PHVS)September 24, 2024 | markets.businessinsider.comJones Trading Initiates Coverage of Pharvaris N.V. (PHVS) with Buy RecommendationSeptember 21, 2024 | msn.comPromising Oral HAE Treatment Deucrictibant Poised for Blockbuster Sales: A Buy Rating AnalysisSeptember 19, 2024 | markets.businessinsider.comBuy Rating on Pharvaris: Promising Results and Strategic Market Position for HAE TreatmentSeptember 10, 2024 | markets.businessinsider.comPharvaris Provides Business Update and Expands Development Program for DeucrictibantSeptember 5, 2024 | globenewswire.comPharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024September 5, 2024 | globenewswire.comPharvaris Presents Data at the Bradykinin Symposium 2024September 5, 2024 | globenewswire.comMorgan Stanley Sticks to Its Buy Rating for Pharvaris (PHVS)September 4, 2024 | markets.businessinsider.comDeucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin SymposiumAugust 28, 2024 | globenewswire.comMorgan Stanley Sticks to Their Buy Rating for Pharvaris (PHVS)August 27, 2024 | markets.businessinsider.comPharvaris (NASDAQ:PHVS) Shares Gap Down to $19.08Pharvaris (NASDAQ:PHVS) Shares Gap Down to $19.08August 27, 2024 | marketbeat.comPharvaris (NASDAQ:PHVS) Stock Price Up 5.2%Pharvaris (NASDAQ:PHVS) Shares Up 5.2%August 26, 2024 | marketbeat.comPharvaris (NASDAQ:PHVS) Stock Price Down 2.4%Pharvaris (NASDAQ:PHVS) Shares Down 2.4%August 23, 2024 | marketbeat.comMorgan Stanley Remains a Buy on Pharvaris (PHVS)August 20, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: CVS Health (CVS), Pharvaris (PHVS) and United Therapeutics (UTHR)August 20, 2024 | markets.businessinsider.comOppenheimer Reaffirms Their Buy Rating on Pharvaris (PHVS)August 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pharvaris on Strong Phase 3 Trial Prospects and Solid Financial PositionAugust 15, 2024 | markets.businessinsider.com Get Pharvaris News Delivered to You Automatically Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter. Email Address PHVS Media Mentions By Week PHVS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PHVS News Sentiment▼0.420.64▲Average Medical News Sentiment PHVS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PHVS Articles This Week▼61▲PHVS Articles Average Week Get Pharvaris News Delivered to You Automatically Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BriaCell Therapeutics News Clever Leaves News Eloxx Pharmaceuticals News enGene News Fortress Biotech News GeoVax Labs News LAVA Therapeutics News Lexaria Bioscience News Procaps Group News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PHVS) was last updated on 1/23/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharvaris Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharvaris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PHVS Stock Alerts